Inventor · disambiguated record
Tomoyuki Igawa
Also filed as: IGAWA TOMOYUKI
108 granted patents·137 pending applications·1,891 citations·filing 2004–2025
99Inventor score
Top patents by PatentIndex Score
245 records- 0198US12122840B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 22, 2024·5 cites·24 claims
- 0298US12116414B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 15, 2024·5 cites·21 claims
- 0398US11168344B2Methods for producing polypeptides by regulating polypeptide associationCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 9, 2021·18 cites·39 claims
- 0498US10934344B2Methods of modifying antibodies for purification of bispecific antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Mar 2, 2021·19 cites·30 claims
- 0598US10253091B2Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Apr 9, 2019·27 cites·35 claims
- 0698US10011858B2Methods for producing polypeptides by regulating polypeptide associationIGAWA TOMOYUKI·Filed 2006·Granted Jul 3, 2018·67 cites·54 claims
- 0798US9828429B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Nov 28, 2017·40 cites·80 claims
- 0898US9096651B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRIGAWA TOMOYUKI·Filed 2008·Granted Aug 4, 2015·90 cites·44 claims
- 0998US8562991B2Antibody molecules that bind to IL-6 receptorIGAWA TOMOYUKI·Filed 2009·Granted Oct 22, 2013·130 cites·19 claims
- 1097US11371039B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 28, 2022·4 cites·30 claims
- 1197US11359194B2Antigen-binding molecule capable of binding two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 14, 2022·4 cites·29 claims
- 1297US11332533B2Modified antibody constant regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted May 17, 2022·13 cites·21 claims
- 1397US11248053B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Feb 15, 2022·16 cites·28 claims
- 1497US11142587B2Method for producing polypeptide hetero-oligomerCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Oct 12, 2021·13 cites·14 claims
- 1597US10472623B2Antigen-binding molecule capable of binding two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 12, 2019·29 cites·21 claims
- 1697US10066018B2Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Sep 4, 2018·28 cites·47 claims
- 1797US9890377B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Feb 13, 2018·34 cites·24 claims
- 1897US9670269B2Methods of modifying antibodies for purification of bispecific antibodiesIGAWA TOMOYUKI·Filed 2007·Granted Jun 6, 2017·43 cites·25 claims
- 1997US9228017B2Antibody constant region variantIGAWA TOMOYUKI·Filed 2010·Granted Jan 5, 2016·44 cites·12 claims
- 2096US11718678B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 8, 2023·7 cites·16 claims
- 2196US11454633B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 27, 2022·4 cites·19 claims
- 2296US10738111B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 11, 2020·17 cites·25 claims
- 2396US10662245B2Methods of reducing IL-6 activity for disease treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted May 26, 2020·22 cites·25 claims
- 2496US10253100B2Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Apr 9, 2019·37 cites·36 claims
- 2596US10000560B2Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of useCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 19, 2018·26 cites·43 claims
- 2696US9868948B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jan 16, 2018·27 cites·34 claims
- 2796US9688762B2Modified antibody constant regionIGAWA TOMOYUKI·Filed 2008·Granted Jun 27, 2017·48 cites·33 claims
- 2896US9334331B2Bispecific antibodiesIGAWA TOMOYUKI·Filed 2011·Granted May 10, 2016·221 cites·33 claims
- 2996US7919086B2Anti-glypican 3 antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2005·Granted Apr 5, 2011·74 cites·56 claims
- 3095US11274151B2CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 15, 2022·11 cites·28 claims
- 3195US11154615B2Library of antigen-binding molecules including modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Oct 26, 2021·8 cites·11 claims
- 3295US10450381B2Methods of treatment that include the administration of bispecific antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Oct 22, 2019·28 cites·84 claims
- 3395US9975966B2Cytotoxicity-inducing theraputic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted May 22, 2018·25 cites·10 claims
- 3495US9969800B2IL-8 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted May 15, 2018·37 cites·36 claims
- 3594US11912989B2Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Feb 27, 2024·3 cites·14 claims
- 3694US11718672B2CD137- and DLL3-targeting multispecific antigen-binding moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Aug 8, 2023·6 cites·28 claims
- 3794US11267868B2Fc region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted Mar 8, 2022·13 cites·3 claims
- 3894US11168139B2Antigen-binding domain, and polypeptide including conveying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 9, 2021·7 cites·8 claims
- 3994US11142563B2Antigen-binding molecule containing modified Fc regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Oct 12, 2021·18 cites·53 claims
- 4094US11124576B2Method for producing polypeptide heteromultimerCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted Sep 21, 2021·20 cites·38 claims
- 4194US11046784B2Methods for controlling blood pharmacokinetics of antibodiesIGAWA TOMOYUKI·Filed 2007·Granted Jun 29, 2021·24 cites·50 claims
- 4294US10919953B2FcgammaRIIB-specific Fc region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Feb 16, 2021·24 cites·8 claims
- 4394US10618965B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeIGAWA TOMOYUKI·Filed 2012·Granted Apr 14, 2020·32 cites·33 claims
- 4494US10519229B2Nucleic acids encoding IL-8 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 31, 2019·22 cites·33 claims
- 4594US8497355B2Anti-glypican-3 antibody having improved kinetics in plasmaIGAWA TOMOYUKI·Filed 2008·Granted Jul 30, 2013·29 cites·16 claims
- 4693US11827699B2Methods for producing antibodies promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 28, 2023·8 cites·20 claims
- 4793US11673947B2Target tissue-specific antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Jun 13, 2023·7 cites·51 claims
- 4893US11180548B2Methods of neutralizing IL-8 biological activityCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Nov 23, 2021·6 cites·11 claims
- 4993US11001643B2Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted May 11, 2021·9 cites·34 claims
- 5093US10759870B2Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 1, 2020·27 cites·61 claims
Showing the top 50 of 245 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tomoyuki Igawa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →